This has led to the hypothesis that subsequent PD-L1 inhibition may restore and sustain systemic immune responses, potentially improving long-term tumor control after chemoradiotherapy (CRT) [5,6,7,8,9,10,11]. This evidence concerns the gene CD274 and neoplasm.